. Author manuscript; available in PMC: 2024 May 6.

Published in final edited form as: Pharmacol Res. 2023 Aug 3;195:106882. doi: 10.1016/j.phrs.2023.106882

Table 4.

Current Studies Combining non-insulin pharmaceuticals and AID.

Author	Drug	Study	Participants	Duration	TIR outcome
Haidar 2020 [157]	Pramlintide	Open-label crossover RCT	28 adults	3 sequences	+ 10% vs AID only
Tsoukas 2021 [158]	Pramlintide	three-way, randomized, blinded, crossover design	7 adults	12 days	no difference between meal + announcement and full carb counting + placebo; + 10% compared to placebo and only meal announcement
Biester 2020 [162]	Dapagliflozin	Double-blind cross-over RCT	15 adolescents and 15 young adults	Single dose	+ 18%
Garcia-Tirado 2022 [159]	Empagliflozin	Open-label cross-over in HCL and PLGS RCT	34 adults	8 weeks	AID + 9.9% PLGS + 16.5%
Haidar 2022 [160]	Empagliflozin	2 × 2 factorial RCT placebo, crossover	24 adults	4 weeks	AID+ 7.2% SAP + 17.5%

RCT: Randomized Controlled Trial; AID: Automated Insulin Delivery; SAP: sensor-augmented pump; PLGS: predicted low glucose system